Loading news...
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Broker upgrades odds on AVANZAR lung cancer trial after arguing repeated delays signal strong results in treatment arm Jefferies has lifted its price target on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, from 15,000p to 18,000p, reiterating a 'buy' recommendation, arguing that the drugmaker is better positioned for long-term growth than the market appreciates. The broker's analysts have reversed their cautious stance on AVANZAR, a phase III clinical trial testing AZ's cancer drug Datroway (datopotamab deruxtecan) combined with immunotherapy Imfinzi and chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Broker upgrades odds on AVANZAR lung cancer trial after arguing repeated delays signal strong results in treatment arm Jefferies has lifted its price target...
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Ozempic, Mounjaro and other GLP-1 drugs for diabetes can prevent the formation of new substance use disorders and alleviate existing addictions, according to findings from a large study of U.S. military veterans.
AstraZeneca PLC (LON: AZN - Get Free Report)'s stock price passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of £131.87 and traded as high as £153.11. AstraZeneca shares last traded at £152.52, with a volume of 17,760,967 shares trading hands. Analyst Upgrades and Downgrades A number
Becker Capital Management Inc. trimmed its holdings in shares of AstraZeneca PLC (NASDAQ: AZN) by 2.2% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 365,300 shares of the company's stock after selling 8,047 shares during the period. Becker Capital
American Century Companies Inc. raised its stake in AstraZeneca PLC (NASDAQ: AZN) by 40.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,187,050 shares of the company's stock after purchasing an additional 626,724 shares during the quarter. American
Shares of AstraZeneca PLC (NASDAQ: AZN - Get Free Report) have received an average recommendation of "Moderate Buy" from the ten research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and nine have issued a buy recommendation on the company. The average 1-year target price
For 2025, we underperformed the Benchmark, while to a lesser extent also trailing our all-cap international growth Proxy Benchmark. The underperformance was in our view attributable to an abrupt but material correction in several holdings over the potential exposure of quality growth franchises to AI disruption. Lundin Mining Corporation shares rose meaningfully during the fourth quarter after the company raised its 2025 copper production outlook and lowered its cash cost guidance.
Mustang Bio (NASDAQ: MBIO - Get Free Report) and AstraZeneca (NASDAQ: AZN - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations. Analyst Recommendations This is a breakdown of current recommendations
The long-term growth story for AstraZeneca PLC beyond 2030 is increasingly focused on next-generation cell therapies and immune engagers, according to UBS, driving an increase to its price target and reiterated 'buy' rating. Analyst Matthew Weston said the company and the wider sector face a "significant patent cliff" around 2030-and-beyond but argues the FTSE 100 drugmaker is well positioned to manage this with "sector leading replacement power".
Brucke Financial Inc. boosted its holdings in shares of AstraZeneca PLC (NASDAQ: AZN) by 33.3% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,476 shares of the company's stock after purchasing an additional 2,869 shares during the period.
Insights into David Herro (Trades, Portfolio)'s Investment Strategy and Recent Portfolio Adjustments David Herro (Trades, Portfolio), a renowned value investor
AstraZeneca Chief Executive Pascal Soriot's 2025 pay rose 6.4% to 17.7 million pounds ($23.87 million) boosted by higher annual bonuses, keeping him among the FTSE 100's highest-paid executives, a filing showed on Tuesday.
Guru Stock PicksGeorge Soros has made the following transactions:Reduce in SPSB by 5.19%Sold out in MMYTAdd in AAMI by 61.3%New position in COINStock News Blue
AZN's stronger growth outlook and 2030 revenue target may outshine PFE's yield and cheaper valuation.
Stock News Oil climbs on Iran risk: Crude headed for its first weekly gain in three weeks as tensions rose over potential U.S. strikes on Iran and possible Stra
Factory Mutual Insurance Co. bought a new stake in AstraZeneca PLC (NASDAQ: AZN) during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 57,852 shares of the company's stock, valued at approximately $4,438,000. A number of other hedge funds have also made changes
Axxcess Wealth Management LLC lifted its stake in shares of AstraZeneca PLC (NASDAQ: AZN) by 17.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,530 shares of the company's stock after purchasing an additional 3,541 shares during the period. Axxcess Wealth